project id: TCGA-PRAD; case submitter id: TCGA-EJ-7325; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.89; age at index: 63; days to birth: -23029; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1948; age at diagnosis: 23029; ajcc clinical m: M0; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1070.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; days to collection: 855; initial weight: 480.0; oct embedded: true; sample id: 6c83b5fa-4647-4977-b0cf-8a33944b1bd5; sample submitter id: TCGA-EJ-7325-01B; portion id: e87d745b-7dbe-4c22-bfa9-dfe4ccf92c60; portion submitter id: TCGA-EJ-7325-01B-11; slide id: 0a7babe2-2e28-4fe3-bb6d-e9a0ba1ee2c2; slide submitter id: TCGA-EJ-7325-01B-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 40.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0; section location: TOP;